SNY Sanofi

   By Stephen Nakrosis 
 

Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY) on Monday announced the U.S. Food and Drug Administration gave its approval for Dupixent as a treatment for adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis.

Atopic dermatitis causes skin to become red, itchy and scaly.

A Phase 3 trial evaluating Dupixent monotherapy in adolescent patients with uncontrolled moderate-to-severe atopic dermatitis demonstrated the safety and efficacy generally were consistent with that previously seen in adult studies, the companies said.

Dupixent also is approved in the U.S. for the treatment of some adult patients with eczema and for use with other asthma medicines for maintenance treatment of moderate-to-severe asthma in some patients people aged 12 years and older.

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

March 11, 2019 16:18 ET (20:18 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.